Navigation Links
New Study Shows Ketamine May Regenerate Brain Cells, Relieving Depression with Lasting Benefit

DENVER, March 17, 2016 /PRNewswire/ -- A new study gives depression sufferers much hope if only they can get their doctors to look at this study. Ketamine infusion therapy, the controversial treatment for depression, has been resisted by many physicians due to concerns about short-lived benefits, risks of addiction, and the lack of large scale studies. In contrast, this retrospective study of over three years of clinical experience, shows lasting benefits for many patients, with no apparent risk of addiction. Through a handful of ketamine infusions directed by Theodore Henderson, MD, PhD, refractory depression symptoms can be relieved significantly and persistently. Evidence points to the regeneration of brain cells as a critical mechanism for the relief of depression, as published in peer-reviewed journal Neural Regeneration Research, February 2016 issue.

Photo -

The study, "Practical application of the neuroregenerative properties of ketamine: real world treatment experience," addresses key points in the controversy surrounding the use of intravenous ketamine for the treatment of depression. Its findings stand in direct contrast to warnings from the American Psychiatric Association (APA).

While controversial in academic settings, Dr. Henderson said his direct experience supports a different strategy for multiple-infusion treatment regimens and his clinical experience shows ketamine can invoke long-lasting effects often with less than six infusions.

"The wealth of clinical experience from treating hundreds of patients with ketamine has supplanted the preliminary data that emerged from the initial open-label and small double-blinded studies," said Dr. Henderson, who is a board certified psychiatrist, specializing in diagnosing and treating complex conditions, based in Denver, Colorado. He is also the co-founder of Neuro-Luminance Ketamine Infusion Centers.

Patients in the study completed the Quick Inventory of Depressive Symptoms (QIDS-SR), among other scales, and 80% showed persistent positive response to the ketamine infusions treatments.

What is a Ketamine Infusion?

Ketamine is a dissociative anesthetic in use since 1970's. Intravenous administration over a prolonged period of time is key to its persistent antidepressant benefit.

Depression is associated with neuron loss, reduced synapse numbers, and dearborization of dendrites. Ketamine appears to potently induce mechanisms which reverse these neuro-degenerative processes. Citing over 60 published scientific research studies, the new research article also reviews the molecular mechanisms by which ketamine invokes a robust activation of the brain's own repair mechanisms. Another conclusion Dr. Henderson highlights is ketamine infusions can relieve refractory depression symptoms persistently, perhaps for years.

"Activation of brain-derived neurotrophic factor (BDNF) appears to have an important role in the antidepressant effects of ketamine. BDNF induces synaptogenesis, dendritic arborization, improved neuronal health, and neurogenesis. These processes likely underlie the persistent benefits of ketamine."

Dr. Henderson's findings challenge the oft-held beliefs that ketamine must be given frequently to have any benefit and that ketamine has no long-lasting benefit. 

Dr. Henderson stated, "Misconceptions about ketamine abound among psychiatrists, particularly related to possible chemical dependence problems. However, the neurobiological basis of its benefit for depression has nothing to do with causing addictive risk. Our patients get better after a few infusions and from there treatments can be discontinued." The study also challenges concerns about neurotoxicity and a recent hypothesis that patients must experience hallucinations during ketamine infusion in order to have an anti-depressant benefit.

Please visit Neuro-Luminance or call (855) 978-0808 for more information.

Media Contact: David Jahr, (949) 874-2667

SOURCE Neuro-Luminance
Copyright©2016 PR Newswire.
All rights reserved

Related medicine technology :

1. Lilly Announces Change to Primary Endpoint of EXPEDITION3 Study
2. New Study Shows that Genetic Information from Prostate Needle Biopsy May Be Used to Predict Tumor Aggressiveness
3. AcelRx Pharmaceuticals Advances ARX-04 into Extension Phase of Open-Label Phase 3 Emergency Room Study
4. Quark Pharmaceuticals Doses First Patients in Two Pivotal Phase III Studies and One Phase II Study of RNAi-Based Therapeutics for Kidney and Eye Indications
5. Eiger Announces Completion of Enrollment of Phase 2 LOWR HDV - 4 (LOnafarnib With Ritonavir in Hepatitis Delta Virus - 4) Study at Hannover Medical School
6. Study Highlights Best Practices in Globalizing Medical Science Liaison Programs
7. Regeneron and Sanofi Announce Topline Results of Phase 3 Monotherapy Study Demonstrating Superiority of Sarilumab vs. Adalimumab in Patients with Active Rheumatoid Arthritis
8. BioElectronics Invited to Present Chronic Pain Patient Observation Study at the British Pain Society Congress
9. Tobira Therapeutics Announces Publication of CENTAUR Phase 2b Study Design and Rationale in Contemporary Clinical Trials
10. Inari Medical Announces IDE Approval To Study The FlowTriever System For The Treatment Of Pulmonary Embolism
11. Stealth BioTherapeutics Initiates Phase 2 Clinical Study Of Elamipretide In Fuchs Corneal Endothelial Dystrophy
Post Your Comments:
(Date:10/2/2017)... 2017 Diplomat Pharmacy, Inc. (NYSE: ... Consulting, LLC , and named its founder as Diplomat,s ... Tennessee , will operate under Diplomat ... service offerings for health care partners to include IT ... "In an interoperable world, technology delivers comprehensive ...
(Date:10/2/2017)... 2, 2017 The Rebound mobile app is poised ... reverse the tide of prescription drug addiction. The app empowers ... intake and stepping down their dosage in a safe, controlled ... December 2017; the first 100,000 people to sign up will ... ...
(Date:9/27/2017)... Sept. 27, 2017  DarioHealth Corp. (NASDAQ: DRIO), a leading global digital ... its MyDario product is expected to appear on The Dr. Oz Show ... Oz Show airs in your area: ... The nine-time Emmy award-winning, The Dr. Oz Show kicked off ... The segment features ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... 13, 2017 , ... Yisrayl Hawkins, Pastor and Overseer at The House of ... popular and least understood books in the Holy Scriptures, Revelation. The Book of Revelation ... scholars for centuries. Many have tossed it off as mere rubbish, but Yisrayl Hawkins ...
(Date:10/13/2017)... ... ... “The Journey: From the Mountains to the Mission Field”: the story of a ... “The Journey: From the Mountains to the Mission Field” is the creation of published ... all ages and currently teaches a class of ladies at her church, which she ...
(Date:10/12/2017)... ... October 12, 2017 , ... CitiDent and San Francisco dentists, ... cutting-edge Oventus O2Vent technology. As many as 18 million Americans are estimated to ... breathing. Oral appliances can offer significant relief to about 75 percent of people ...
(Date:10/12/2017)... ... , ... IsoComforter, Inc. ( ), one of the Nation’s ... design of the shoulder pad. The shoulder pad provides optimal support and full ... while using cold therapy. By utilizing ice and water that is circulated from an ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... ... drug delivery system that we intend to develop to enable prevention of a ... lead to severe hearing loss, especially in pediatric patients. For cisplatin, hearing loss ...
Breaking Medicine News(10 mins):